Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):856–860. doi: 10.1038/bjc.1993.157

Advanced breast cancer: use of resources and cost implications.

M A Richards 1, S Braysher 1, W M Gregory 1, R D Rubens 1
PMCID: PMC1968338  PMID: 8471446

Abstract

Little information is currently available on the use of hospital resources and the resulting costs of treating any advanced cancer. Such data may be useful for planning purposes and for calculating the cost effectiveness of measures designed to reduce the incidence of advanced disease (such as the National Breast Screening Programme). A retrospective analysis of the medical records of 50 patients with advanced breast cancer who attended the Guy's Hospital Oncology Unit and who died between October 1988 and December 1990 has therefore been undertaken. For each patient, the duration of in-patient stays and principal indications for admissions were recorded, together with the number of out-patient attendances. Details of endocrine treatment, chemotherapy and radiotherapy were abstracted as were all radiological and laboratory investigations. Costs for each of these activities were calculated. The median duration of advanced disease was 17 months (mean 27 months; range 7 days-12 years). The mean cost of treatment per patients was calculated to be 7,620 pounds (range 317 pounds-27,860 pounds). Mean duration of in-patient stay was 32 days (0-133) and this accounted for 56% of total costs. The large majority (> 80%) of the time spent as an in-patient was for the care of serious illness rather than for specific antitumour treatment. Cytotoxic drugs accounted for 9% of the total cost, compared with 8% for radiotherapy and 13% for laboratory and radiological investigations.

Full text

PDF
856

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atherton L. The cost of radiotherapy treatments on a linear accelerator. Br J Radiol. 1984 Jan;57(673):106–107. doi: 10.1259/0007-1285-57-673-106. [DOI] [PubMed] [Google Scholar]
  2. Baker M. S., Kessler L. G., Urban N., Smucker R. C. Estimating the treatment costs of breast and lung cancer. Med Care. 1991 Jan;29(1):40–49. doi: 10.1097/00005650-199101000-00004. [DOI] [PubMed] [Google Scholar]
  3. Borgelt B., Gelber R., Kramer S., Brady L. W., Chang C. H., Davis L. W., Perez C. A., Hendrickson F. R. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1–9. doi: 10.1016/0360-3016(80)90195-9. [DOI] [PubMed] [Google Scholar]
  4. Ellis B. W. Management importance of common treatments: contribution of top 20 procedures to surgical workload and cost. BMJ. 1991 Apr 13;302(6781):882–884. doi: 10.1136/bmj.302.6781.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Friedlander M. L., Tattersall M. H. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol. 1982 Dec;18(12):1237–1241. doi: 10.1016/0277-5379(82)90124-9. [DOI] [PubMed] [Google Scholar]
  6. Gelber R. D., Larson M., Borgelt B. B., Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981 Oct 15;48(8):1749–1753. doi: 10.1002/1097-0142(19811015)48:8<1749::aid-cncr2820480810>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  7. Goddard M., Maher E. J., Hutton J., Shah D. Palliative radiotherapy--counting the costs of changing practice. Health Policy. 1991 Apr;17(3):243–256. doi: 10.1016/0168-8510(91)90127-j. [DOI] [PubMed] [Google Scholar]
  8. Greene D. The cost of radiotherapy treatments on a linear accelerator. Br J Radiol. 1983 Mar;56(663):189–191. doi: 10.1259/0007-1285-56-663-189. [DOI] [PubMed] [Google Scholar]
  9. Hurley S. F., Huggins R. M., Snyder R. D., Bishop J. F. The cost of breast cancer recurrences. Br J Cancer. 1992 Mar;65(3):449–455. doi: 10.1038/bjc.1992.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lobo P. J., Powles R. L., Hanrahan A., Reynold D. K. Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes. BMJ. 1991 Feb 9;302(6772):323–326. doi: 10.1136/bmj.302.6772.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mattsson W., Gynning I., Carlsson B., Mauritzon S. E. Cancer chemotherapy in advanced malignant disease. A cost benefit analysis. Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):509–520. doi: 10.3109/02841867909129080. [DOI] [PubMed] [Google Scholar]
  12. Rubens R. D. Auditing palliative cancer chemotherapy. Eur J Cancer. 1990;26(10):1023–1025. doi: 10.1016/0277-5379(90)90041-q. [DOI] [PubMed] [Google Scholar]
  13. de Koning H. J., van Ineveld B. M., de Haes J. C., van Oortmarssen G. J., Klijn J. G., van der Maas P. J. Advanced breast cancer and its prevention by screening. Br J Cancer. 1992 Jun;65(6):950–955. doi: 10.1038/bjc.1992.199. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES